Dermira, Inc. (DERM) Forms $24.69 Double Bottom; CI FINANCIAL CORPORATION OR (CIFAF) Sellers Increased By 2.95% Their Shorts

December 7, 2017 - By Ellis Scott

Dermira, Inc. (DERM) formed double bottom with $23.95 target or 3.00% below today’s $24.69 share price. Dermira, Inc. (DERM) has $1.03 billion valuation. The stock decreased 0.04% or $0.01 during the last

trading session, reaching $24.69. About 57,668 shares traded. Dermira, Inc. (NASDAQ:DERM) has declined 7.44% since December 7, 2016 and is downtrending. It has underperformed by 24.14% the S&P500.

CI FINANCIAL CORPORATION OR (OTCMKTS:CIFAF) had an increase of 2.95% in short interest. CIFAF’s SI was 2.63 million shares in December as released by FINRA. Its up 2.95% from 2.56 million shares previously. With 15,800 avg volume, 167 days are for CI FINANCIAL CORPORATION OR (OTCMKTS:CIFAF)’s short sellers to cover CIFAF’s short positions. It closed at $22.56 lastly. It is down 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

CI Financial Corp. is a publicly owned asset management holding company. The company has market cap of $6.25 billion. Through its subsidiaries, the firm manages separate client focused equity, fixed income, and alternative investments portfolios. It has a 15.67 P/E ratio. It also manages mutual funds, hedge funds, and fund of funds for its clients through its subsidiaries.

Investors sentiment decreased to 1.39 in 2017 Q2. Its down 0.50, from 1.89 in 2017Q1. It worsened, as 21 investors sold Dermira, Inc. shares while 28 reduced holdings. 20 funds opened positions while 48 raised stakes. 39.55 million shares or 17.43% more from 33.68 million shares in 2017Q1 were reported. Boothbay Fund Mngmt Llc, a New York-based fund reported 21,942 shares. State Board Of Administration Of Florida Retirement Systems holds 13,433 shares. Loomis Sayles And Lp reported 435,480 shares or 0.03% of all its holdings. Pennsylvania-based Sei Investments has invested 0.02% in Dermira, Inc. (NASDAQ:DERM). 112 are owned by Bancshares Of Montreal Can. Century has invested 0% in Dermira, Inc. (NASDAQ:DERM). Nea Mgmt Ltd Co stated it has 3.72% of its portfolio in Dermira, Inc. (NASDAQ:DERM). Td Asset Management Incorporated has invested 0% of its portfolio in Dermira, Inc. (NASDAQ:DERM). Abingworth Llp owns 70,000 shares for 1.62% of their portfolio. Amer Group holds 0% or 23,641 shares. Citadel Advsr Ltd Liability Com stated it has 7,750 shares or 0% of all its holdings. Iguana Healthcare Llc accumulated 140,000 shares. Point72 Asia (Hong Kong) Limited reported 339 shares stake. Creative Planning reported 1,961 shares stake. Swiss Bancorporation accumulated 49,800 shares.

Analysts await Dermira, Inc. (NASDAQ:DERM) to report earnings on February, 27. They expect $-1.29 EPS, down 514.29% or $1.08 from last year’s $-0.21 per share. After $-1.21 actual EPS reported by Dermira, Inc. for the previous quarter, Wall Street now forecasts 6.61% negative EPS growth.

Among 9 analysts covering Dermira Inc (NASDAQ:DERM), 8 have Buy rating, 1 Sell and 0 Hold. Therefore 89% are positive. Dermira Inc had 19 analyst reports since August 7, 2015 according to SRatingsIntel. As per Wednesday, August 19, the company rating was initiated by Cowen & Co. Needham maintained Dermira, Inc. (NASDAQ:DERM) rating on Friday, January 8. Needham has “Buy” rating and $38.0 target. As per Tuesday, July 25, the company rating was maintained by Cantor Fitzgerald. The rating was maintained by Mizuho with “Buy” on Thursday, September 7. The stock of Dermira, Inc. (NASDAQ:DERM) earned “Buy” rating by Leerink Swann on Tuesday, November 7. Needham maintained Dermira, Inc. (NASDAQ:DERM) on Wednesday, May 11 with “Buy” rating. The firm earned “Buy” rating on Friday, September 15 by Needham. The firm has “Buy” rating given on Friday, December 18 by Citigroup. On Tuesday, December 5 the stock rating was initiated by Guggenheim with “Buy”. The firm earned “Buy” rating on Tuesday, November 7 by Needham.


Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.